BioMimetix is developing a new class of redox active metalloporphyrin’s for the treatment of inflammatory skin disease and the treatment of cancer patients undergoing radiation therapy and chemotherapy.

These compounds act by modulating key nuclear transcription factors to broadly inhibit inflammatory pathways while also stimulating the production of antioxidants.

Dermatology

Improving Quality of Life by controlling chronic inflammatory skin conditions and their disabling symptoms including itch, pain and appearance.

Oncology

Protecting patients with cancer from the severe and disabling side effects of radiation therapy and chemotherapy while also augmenting control of the underlying cancer.